c-erbB-2 and p53 expression in fallopian tube carcinoma

Martha Lacy, L. C. Hartmann, Gary Keeney, S. C. Cha, H. S. Wieand, K. C. Podratz, P. C. Roche

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Background. Carcinoma of the fallopian tube is a rare gynecologic malignancy. Its histologic appearance and patterns of spread are similar to those of epithelial ovarian cancer. Alterations in the gene products of c- erbB-2 (HER-2/neu) and p53 are found commonly in ovarian tumors and may have prognostic relevance. The authors sought to determine whether tubal cancers are biologically similar to ovarian cancer with respect to the expression of these two molecular markers. Methods. A cohort of 43 patients with fallopian tube cancer was studied. Immunohistochemical staining for c-erbB-2 and p53 was performed on pretreatment tissue blocks. Clinical information was available for all patients, with a median follow-up of 9 years. Clinicopathologic correlations were made. Results. Nine patients had Stage I disease, 11 had Stage II disease, 18 had Stage III disease, and 5 had Stage IV disease, with a median survival was 85 months. c-erbB-2 overexpression was found in 11 cases (25.6%), and p53 positivity was noted in 26 cases (60.5%). Log rank survival curves showed no association between staining for c-erbB-2 or p53 expression and clinical outcome. A multivariate analysis identified patient age older than 65 years (P = 0.05) and Stage III or IV disease (P = 0.0065) as the only variables that predicted poor outcome. Conclusions. Fallopian tube cancers are similar to ovarian cancer with respect to the proportion of tumors with abnormal expression of c-erbB-2 and p53. The authors could not demonstrate that these two molecular markers had prognostic relevance in this disease, but the size of their cohort was limited. However, the potential prognostic relevance of c-erbB-2 and p53 expression in tubal cancers should he pursued in a larger cohort.

Original languageEnglish (US)
Pages (from-to)2891-2896
Number of pages6
JournalCancer
Volume75
Issue number12
DOIs
StatePublished - 1995

Fingerprint

Fallopian Tubes
Carcinoma
Fallopian Tube Neoplasms
Neoplasms
Ovarian Neoplasms
Staining and Labeling
erbB-2 Genes
Survival
Multivariate Analysis

Keywords

  • cerbB2 (HER-2/neu)
  • fallopian tube neoplasm
  • immunohistochemistry
  • p53

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

c-erbB-2 and p53 expression in fallopian tube carcinoma. / Lacy, Martha; Hartmann, L. C.; Keeney, Gary; Cha, S. C.; Wieand, H. S.; Podratz, K. C.; Roche, P. C.

In: Cancer, Vol. 75, No. 12, 1995, p. 2891-2896.

Research output: Contribution to journalArticle

Lacy, Martha ; Hartmann, L. C. ; Keeney, Gary ; Cha, S. C. ; Wieand, H. S. ; Podratz, K. C. ; Roche, P. C. / c-erbB-2 and p53 expression in fallopian tube carcinoma. In: Cancer. 1995 ; Vol. 75, No. 12. pp. 2891-2896.
@article{f516cb93dd07494da252aa3c777ab97a,
title = "c-erbB-2 and p53 expression in fallopian tube carcinoma",
abstract = "Background. Carcinoma of the fallopian tube is a rare gynecologic malignancy. Its histologic appearance and patterns of spread are similar to those of epithelial ovarian cancer. Alterations in the gene products of c- erbB-2 (HER-2/neu) and p53 are found commonly in ovarian tumors and may have prognostic relevance. The authors sought to determine whether tubal cancers are biologically similar to ovarian cancer with respect to the expression of these two molecular markers. Methods. A cohort of 43 patients with fallopian tube cancer was studied. Immunohistochemical staining for c-erbB-2 and p53 was performed on pretreatment tissue blocks. Clinical information was available for all patients, with a median follow-up of 9 years. Clinicopathologic correlations were made. Results. Nine patients had Stage I disease, 11 had Stage II disease, 18 had Stage III disease, and 5 had Stage IV disease, with a median survival was 85 months. c-erbB-2 overexpression was found in 11 cases (25.6{\%}), and p53 positivity was noted in 26 cases (60.5{\%}). Log rank survival curves showed no association between staining for c-erbB-2 or p53 expression and clinical outcome. A multivariate analysis identified patient age older than 65 years (P = 0.05) and Stage III or IV disease (P = 0.0065) as the only variables that predicted poor outcome. Conclusions. Fallopian tube cancers are similar to ovarian cancer with respect to the proportion of tumors with abnormal expression of c-erbB-2 and p53. The authors could not demonstrate that these two molecular markers had prognostic relevance in this disease, but the size of their cohort was limited. However, the potential prognostic relevance of c-erbB-2 and p53 expression in tubal cancers should he pursued in a larger cohort.",
keywords = "cerbB2 (HER-2/neu), fallopian tube neoplasm, immunohistochemistry, p53",
author = "Martha Lacy and Hartmann, {L. C.} and Gary Keeney and Cha, {S. C.} and Wieand, {H. S.} and Podratz, {K. C.} and Roche, {P. C.}",
year = "1995",
doi = "10.1002/1097-0142(19950615)75:12<2891::AID-CNCR2820751216>3.0.CO;2-B",
language = "English (US)",
volume = "75",
pages = "2891--2896",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "12",

}

TY - JOUR

T1 - c-erbB-2 and p53 expression in fallopian tube carcinoma

AU - Lacy, Martha

AU - Hartmann, L. C.

AU - Keeney, Gary

AU - Cha, S. C.

AU - Wieand, H. S.

AU - Podratz, K. C.

AU - Roche, P. C.

PY - 1995

Y1 - 1995

N2 - Background. Carcinoma of the fallopian tube is a rare gynecologic malignancy. Its histologic appearance and patterns of spread are similar to those of epithelial ovarian cancer. Alterations in the gene products of c- erbB-2 (HER-2/neu) and p53 are found commonly in ovarian tumors and may have prognostic relevance. The authors sought to determine whether tubal cancers are biologically similar to ovarian cancer with respect to the expression of these two molecular markers. Methods. A cohort of 43 patients with fallopian tube cancer was studied. Immunohistochemical staining for c-erbB-2 and p53 was performed on pretreatment tissue blocks. Clinical information was available for all patients, with a median follow-up of 9 years. Clinicopathologic correlations were made. Results. Nine patients had Stage I disease, 11 had Stage II disease, 18 had Stage III disease, and 5 had Stage IV disease, with a median survival was 85 months. c-erbB-2 overexpression was found in 11 cases (25.6%), and p53 positivity was noted in 26 cases (60.5%). Log rank survival curves showed no association between staining for c-erbB-2 or p53 expression and clinical outcome. A multivariate analysis identified patient age older than 65 years (P = 0.05) and Stage III or IV disease (P = 0.0065) as the only variables that predicted poor outcome. Conclusions. Fallopian tube cancers are similar to ovarian cancer with respect to the proportion of tumors with abnormal expression of c-erbB-2 and p53. The authors could not demonstrate that these two molecular markers had prognostic relevance in this disease, but the size of their cohort was limited. However, the potential prognostic relevance of c-erbB-2 and p53 expression in tubal cancers should he pursued in a larger cohort.

AB - Background. Carcinoma of the fallopian tube is a rare gynecologic malignancy. Its histologic appearance and patterns of spread are similar to those of epithelial ovarian cancer. Alterations in the gene products of c- erbB-2 (HER-2/neu) and p53 are found commonly in ovarian tumors and may have prognostic relevance. The authors sought to determine whether tubal cancers are biologically similar to ovarian cancer with respect to the expression of these two molecular markers. Methods. A cohort of 43 patients with fallopian tube cancer was studied. Immunohistochemical staining for c-erbB-2 and p53 was performed on pretreatment tissue blocks. Clinical information was available for all patients, with a median follow-up of 9 years. Clinicopathologic correlations were made. Results. Nine patients had Stage I disease, 11 had Stage II disease, 18 had Stage III disease, and 5 had Stage IV disease, with a median survival was 85 months. c-erbB-2 overexpression was found in 11 cases (25.6%), and p53 positivity was noted in 26 cases (60.5%). Log rank survival curves showed no association between staining for c-erbB-2 or p53 expression and clinical outcome. A multivariate analysis identified patient age older than 65 years (P = 0.05) and Stage III or IV disease (P = 0.0065) as the only variables that predicted poor outcome. Conclusions. Fallopian tube cancers are similar to ovarian cancer with respect to the proportion of tumors with abnormal expression of c-erbB-2 and p53. The authors could not demonstrate that these two molecular markers had prognostic relevance in this disease, but the size of their cohort was limited. However, the potential prognostic relevance of c-erbB-2 and p53 expression in tubal cancers should he pursued in a larger cohort.

KW - cerbB2 (HER-2/neu)

KW - fallopian tube neoplasm

KW - immunohistochemistry

KW - p53

UR - http://www.scopus.com/inward/record.url?scp=0029037084&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029037084&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19950615)75:12<2891::AID-CNCR2820751216>3.0.CO;2-B

DO - 10.1002/1097-0142(19950615)75:12<2891::AID-CNCR2820751216>3.0.CO;2-B

M3 - Article

C2 - 7773939

AN - SCOPUS:0029037084

VL - 75

SP - 2891

EP - 2896

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 12

ER -